

## References

### S-213

1. Bakhuraysah M, Siatskas C, Petratos S. Hematopoietic stem cell transplantation for multiple sclerosis: Is it a clinical reality? *Stem Cell Res Ther.* 2016;7:12
2. Malmegrim K, Azevedo J, Amuda L, et al. Immunological balance is associated with clinical outcome after autologous hematopoietic stem cell transplantation in type 1 diabetes. *Front Immunol.* 2017;8:167.
3. Farge D, Arruda L, Brigant F, et al. Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients. *J Hematol Oncol.* 2017;10:21.
4. Muraro PA, Pasquini M, Atkins HL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. *JAMA Neurol.* 2017;74(4):459-469.
5. Atkins HL, Bowman M, Allan D., et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. *Lancet.* 2016;576-585.
6. Mancardi GL, Sormani MP, Gualandi F, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis; A phase II trial. *Neurology.* 2015;84:981–988.
7. van Laar JM, Naraghi K, Tyndall A. Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis. *Rheumatology (Oxford).* 2015;54(12):2126-2133.
8. van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: A randomized clinical trial. *JAMA.* 2014;311(24):2490-2498.
9. Hayes, Inc. Hayes Health Technology Brief. *High-Dose Immunosuppressive Therapy with Hematopoietic Transplantation for Treatment of Multiple Sclerosis.* Lansdale, PA: Hayes, Inc.; January, 2018.
10. Hayes, Inc. Hayes Health Technology Brief. *High-Dose Immunosuppressive Therapy with Hematopoietic Stem Cell Transplantation for the Treatment of Systemic Sclerosis.* Lansdale, PA: Hayes, Inc.; February, 2018
11. Snowden JA, Sharrack B, Akil M, et al. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist. *Clinical Medicine (London, England).* 2018;18(4):329-334.
12. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2015;21(11):1863-1869.

13. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology*. 2016;87(4):419-425.
14. Sullivan K, Goldmuntz E, Keyes-Elstein L, et al. Myeloblastic autologous stem cell for severe scleroderma. *N. Engl J Med*. 2018;378(1):35-47.
15. Host L, Nikpour M, Calderone A, Cannell P, Roddy J. Autologous stem cell transplantation in systemic sclerosis: a systematic review. *Clin Exp Rheumatol*. 2017;35 Suppl 106(4):198-207.
16. Patel L, Lim YJ, Randomized trials of autologous hematopoietic stem cell transplantation for diffuse cutaneous systemic sclerosis: systematic review and meta-analysis with trial sequential analysis of overall mortality *Blood*. 2018;132:612.
17. Muraro PA, Pasquini M, Atkins HL, et al. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. *JAMA Neurology*. 2017;74(4):459-469.
18. Hayes, Inc. Hayes Health Technology Assessment. *Autologous hematopoietic stem cell transplantation for the treatment of systemic sclerosis*. Lansdale, PA: Hayes, Inc.; Published on 7/19/2019. Accessed on 4/03/2020.
19. Sullivan KM, Majhail NS, Bredeson C, et al. Systemic sclerosis as an indication for autologous hematopoietic cell transplantation” Position statement from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2018; 24:1961-1964.
20. Shouval R, Furie N, Raanani P, Nagler A, Gafter-Gvili A. Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis. *Biol Blood Marrow Transplant*. 2018; 24(5):937-944.
21. Burt RK, Balabanov R, Burman J, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. *JAMA*. 2019; 321(2):165-174.
22. Sormani MP, Muraro PA, Schiavetti I, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis. *Neurol*. 2017; 88(22):2115-2122.
23. Ge F, Lin H, Li A, Chang T. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: A systematic review and meta-analysis. *Neurol Sci*, 2019; 40(3):479-487.
24. Snarski E, Milczarczyk A, Halaburda K, et al. Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: long-term observations. *Bone Marrow Transplant*. 2016; 51(3):398-402.

25. Shevchenko JL, Kuznetsov AN, Ionova TI, et al. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives. *Ann Hematol.* 2015; 94(7):1149-1157.
26. Burt RK, Balabanov R, Han X, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. *JAMA.* 2015; 313(3):275-84.
27. Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. *Neurology.* 2017; 88(9):842–852.
28. Leone A, Radin M, Almarzooqi AM, et al. Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. *Autoimmun Rev.* 2017; 16(5):469-477.
29. Leng XM, Jiang Y, Zhou DB, et al. Good outcome of severe lupus patients with high-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation: a 10-year follow-up study. *Clin Exp Rheumatol.* 2017; 35(3):494-499.
30. Cao C, Wang M, Sun J, et al. Autologous peripheral blood haematopoietic stem cell transplantation for systemic lupus erythematosus: the observation of long-term outcomes in a Chinese centre. *Clin Exp Rheumatol.* 2017; 35(3):500-507.
31. Burt RK, Han X, Gozdzia P, et al. Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on outcome. *Bone Marrow Transplant.* Jun 2018; 53(6):692-700.
32. M F Silva J, Ladomenou F, Carpenter B, et al. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis. *Blood Adv.* 2018; 2(7):777–786.
33. El-Badawy A, El-Badri N. Clinical Efficacy of Stem Cell Therapy for Diabetes Mellitus: A Meta-Analysis. *PLoS One.* 2016; 11(4):e0151938.
34. Cantu-Rodriguez OG, Lavalle-Gonzalez F, Herrera-Rojas MA, et al. Long-term insulin independence in type 1 diabetes mellitus using a simplified autologous stem cell transplant. *J Clin Endocrinol Metab.* 2016; 101(5):2141-2148.
35. Xiang H, Chen H, Li F, et al. Predictive factors for prolonged remission after autologous hematopoietic stem cell transplantation in young patients with type 1 diabetes mellitus. *Cytotherapy.* 2015; 17(11):1638-1645.
36. Walicka M, Milczarczyk A, Snarski E, et al. Lack of persistent remission following initial recovery in patients with type 1 diabetes treated with autologous peripheral blood stem cell transplantation. *Diabetes Res Clin Pract.* 2018; 143:357-363.

37. Hawkey CJ, Allez M, Clark MM, et al. Autologous hematopoietic stem cell transplantation for refractory Crohn disease: A randomized clinical trial. *JAMA*. 2015; 314(23):2524-2534.
38. Lindsay JO, Allez M, Clark M, et al. Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. *Lancet Gastroenterol Hepatol*. 2017; 2(6):399-406.
39. Brierley CK, Castilla-Llorente C, Labopin M, et al. Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes from the European Society for Blood and Marrow Transplantation. *J Crohns Colitis*. 2018.
40. Bryant A, Atkins H, Pringle CE, et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. *JAMA Neurol*. 2016; 73(6):652-658.
41. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology*. 2016;87(4):419-425.
42. Rae-Grant A, Day GS, Marrie RA, et al. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2018; 90(17):789-800.
43. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2018; 90(17):777-788.
44. Cohen JA, Baldassari LE, Atkins HL et al. Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: Position statement from the American Society for Blood and Marrow Transplantation. *Biol. Blood Marrow Transplant*. 2019 May; 25(5).
45. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis*. Aug 2017;76(8):1327-1339. PMID 27941129
46. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. Apr 2018;113(4):481-517. PMID 29610508
47. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Stem Cell Transplantation (Formerly 110.8.1) (110.23). 2016. Accessed April 6, 2020.